Print
|
Close
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Active:
Yes
Cancer Type:
Bladder Cancer
Unknown Primary
NCT ID:
NCT06510374
Trial Phases:
Phase III
Protocol IDs:
000423 (primary)
NCI-2025-01046
U1111-1284-0685
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Ferring Pharmaceuticals
NCI Full Details:
http://clinicaltrials.gov/show/NCT06510374
Summary
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in
Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Treatment Sites in Georgia
City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.